Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Open access
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., Herrstedt, J.·2018·Annals of Oncology

Abstract

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx758

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 136 references

Research works printed but not linked: 24

  1. Delarue, 2013, Iron parameters and relation to prognosis in elderly patients with aggressive lymphoma receiving first line immunochemotherapy: an analysis of the Lysa LNH 03-6B Study, Blood, 122
  2. Hudis, 2004, rHuEPO and treatment outcomes: the clinical experience, Oncologist, 9, 55, 10.1634/theoncologist.9-90005-55 · doi:10.1634/theoncologist.9-90005-55
  3. Aapro, 2016, Practical recommendations for the treatment of anemia in cancer patients, Malignant Tumors, 4, 368
  4. Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, Br J Haematol, 122, 394, 10.1046/j.1365-2141.2003.04448.x · doi:10.1046/j.1365-2141.2003.04448.x
  5. Aapro, 2009, An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology, Oncologist, 14, 1, 10.1634/theoncologist.2009-S1-1 · doi:10.1634/theoncologist.2009-s1-1
  6. Cazzola, 1995, Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response, Blood, 86, 4446, 10.1182/blood.V86.12.4446.bloodjournal86124446 · doi:10.1182/blood.v86.12.4446.bloodjournal86124446
  7. Moebus, 2013, Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial, J Nat Cancer Inst, 105, 1018, 10.1093/jnci/djt145 · doi:10.1093/jnci/djt145
  8. Aapro, 2015, Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis, Ann Oncol, 26, 688, 10.1093/annonc/mdu579 · doi:10.1093/annonc/mdu579
  9. Galli, 2004, Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma, Haematologica, 89, 1141
  10. Hastka, 1994, Central role of zinc protoporphyrin in staging iron deficiency, Clin Chem, 40, 768, 10.1093/clinchem/40.5.768 · doi:10.1093/clinchem/40.5.768
  11. Aapro, 2011, Too-low iron doses and too many dropouts in negative iron trial?, J Clin Oncol, 29, e525, 10.1200/JCO.2011.35.3219 · doi:10.1200/jco.2011.35.3219
  12. Jaspers, 2015, Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation, Am J Hematol, 90, e133, 10.1002/ajh.24013 · doi:10.1002/ajh.24013
  13. Rezazadeh, 2005, Evidence that iron overload plus croton oil induce skin tumours in mice, Hum Exp Toxicol, 24, 409, 10.1191/0960327105ht544oa · doi:10.1191/0960327105ht544oa
  14. Link, 2013, Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany, Onkologie, 36, 266
  15. Osterborg, 1998, Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?, Med Oncol, 15, S47
  16. Upile, 2009, Blood product transfusion and cancer prognosis, Clin Adv Hematol Oncol, 7, 656
  17. Halabi, 2013, Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis, Am J Surg, 206, 1024, 10.1016/j.amjsurg.2013.10.001 · doi:10.1016/j.amjsurg.2013.10.001
  18. Carson, 2014, Should we universally adopt a restrictive approach to blood transfusion? It's all about the number, Am J Med, 127, 103, 10.1016/j.amjmed.2013.10.026 · doi:10.1016/j.amjmed.2013.10.026
  19. Sanon, 2011, Peripheral arterial ischemic events in cancer patients, Vasc Med, 16, 119, 10.1177/1358863X10388346 · doi:10.1177/1358863x10388346
  20. Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744 · doi:10.1182/blood-2012-04-425744
  21. Ferro, 2012, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies, Kidney Int, 81, 1273, 10.1038/ki.2012.22 · doi:10.1038/ki.2012.22
  22. Krivoshiev, 2008, Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia, Curr Med Res Opin, 24, 1407, 10.1185/030079908X297402 · doi:10.1185/030079908x297402
  23. Haag-Weber, 2009, Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis, Clin Nephrol, 72, 380
  24. Weigang-Köhler, 2009, HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours, Oncol Res Treat, 32, 168, 10.1159/000200783 · doi:10.1159/000200783

Cited by

See all 288

Metadata

Authors
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., & Herrstedt, J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-10
Volume
29
Issue
Suppl 4
Pages
iv96-iv110
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2894700795
Cited by
288
References
136
FWCI
13.03
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1093/annonc/mdx758
The paper
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., Ludwig, H., Österborg, A., Pronzato, P., Santini, V., Schrijvers, D., Stauder, R., Jordan, K., & Herrstedt, J. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. https://doi.org/10.1093/annonc/mdx758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.